<DOC>
	<DOC>NCT00375076</DOC>
	<brief_summary>In a prospective, randomized, double-blind trial, the effects of two different dosages of LMWH (5000 anti-Xa U od sc and 10 000 anti-Xa U od sc daily) on markers of hemostatic system and thrombin generation will be investigated in non-surgical cancer patients will be investigated.</brief_summary>
	<brief_title>Comparison of Two Different Dosages of Low-molecular Weight Heparin in Cancer Patients</brief_title>
	<detailed_description />
	<mesh_term>Heparin, Low-Molecular-Weight</mesh_term>
	<mesh_term>Dalteparin</mesh_term>
	<mesh_term>Heparin</mesh_term>
	<criteria>Patients (&gt; 18 years) with active cancer and at least one of the following indications for thromboprophylaxis with LMWH: Immobilization History of VTE Acute inflammation Heart failure (NYHA class III or IV) Respiratory failure Indication for LMWH or UFH at therapeutic dosages Treatment with antithrombotics (vitamin K antagonists, acetylsalicylic acid, clopidogrel) for reasons other than prevention of VTE (e.g. atrial fibrillation, myocardial infarction) Contraindication for the treatment with LMWH Major surgery within the last 4 weeks; minor surgery within the last week Thrombocytopenia (&lt; 100.000/Î¼l) Prolonged prothrombin time Prolonged activated partial thromboplastin time (aPTT) History of heparininduced thrombocytopenia Bodyweight &lt; 50 kg or &gt; 100 kg Renal insufficiency (creatinine &gt; 2 mg/dl)</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2009</verification_date>
</DOC>